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Abstract
Cytotoxic T lymphocytes (CTLs) are the major killer of virus-infected cells. Granzyme B (GrB) from CTLs induces apoptosis in
target cells by cleavage and activation of substrates like caspase-3 and Bid. However, while undergoing apoptosis, cells are
still capable of producing infectious viruses unless a mechanism exists to specifically inhibit viral production. Using
proteomic approaches, we identified a novel GrB target that plays a major role in protein synthesis: eukaryotic initiation
factor 4 gamma 3 (eIF4G3). We hypothesized a novel role for GrB in translation of viral proteins by targeting eIF4G3, and
showed that GrB cleaves eIF4G3 specifically at the IESD
1408S sequence. Both GrB and human CTL treatment resulted in
degradation of eIF4G3 and reduced rates of translation. When Jurkat cells infected with vaccinia virus were treated with GrB,
there was a halt in viral protein synthesis and a decrease in production of infectious new virions. The GrB-induced inhibition
of viral translation was independent of the activation of caspases, as inhibition of protein synthesis still occurred with
addition of the pan-caspase inhibitor zVAD-fmk. This demonstrated for the first time that GrB prevents the production of
infectious vaccinia virus by targeting the host translational machinery.
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Introduction
One major strategy of the host to survive the attack of viruses is
to induce apoptosis in infected host cells. Cytotoxic T-lymphocytes
(CTLs) play an important role in the apoptosis pathway, which
activates a family of cytosolic proteins called caspases in target
cells. When caspases are activated, they execute the key reactions
that drive target cells to their demise. Activation of initiator
caspases such as caspase-8 and 10 results in direct activation of the
apoptosis executioner caspases like caspase-3 [1]. Caspase-8 and
10 also signal through the mitochondrial pathway by activating a
protein called ‘‘BH3 interacting domain death agonist’’ (Bid) [2,3],
resulting in the release of cytochrome c (cyt c). Soluble cyt c also
mediates the activation of the executioner caspases [1]. Thus,
there is cooperation between the mitochondrial pathway and the
caspase system. Active caspase-3 cleaves ICAD (inhibitor of
caspase-activated deoxyribonuclease), with subsequent release of
CAD and DNA degradation. Other substrates of executioner
caspases include cytoskeletal and nuclear skeletal components like
fodrin and lamin A, which result in cell shrinkage [1].
The mechanism by which CTLs activate the caspase cascade
system has been an active area of research. We now know that
electron dense granules found in CTLs carry cytolytic factors that
trigger apoptosis in target cells. Granules polarize toward the
immune synapse as the membranes of the CTL and target cell
make contact. Cytolytic factors in the granules are then delivered
to the target cell to induce cell death. Two of the first proteins to
be isolated from these granules were perforin [4,5] and granzyme
B (GrB) [6]. Although purified perforin readily lyses cell
membranes, perforin alone is not able to initiate DNA
fragmentation in the same way as treatment with CTLs [7].
Combined treatment with perforin and GrB reproduces the effects
of CTL treatment [8], by inducing both membrane damage and
DNA fragmentation. GrB is a serine protease with an unusual
substrate specificity, cleaving proteins at aspartic acid residues [9].
GrB is initially synthesized as an inactive zymogen that is activated
by the removal of two amino acids at the amino terminus [10]. In
the current model of CTL-mediated killing, perforin plays a role in
granting GrB access to the cytosol of target cells [11]. Through
proteolytic cleavage, GrB activates cytosolic substrates such as
caspases [12,13] and Bid, independent of caspase-8 [14].
Proteolytic activation of Bid results in heterodimerization with
Bax (B-cell CLL/lymphoma 2 (Bcl2) associated X protein) and the
subsequent recruitment of the Bid/Bax complex to the mitochon-
dria. The Bid/Bax complex promotes mitochondrial membrane
depolarization [15] and the release of cyt c and SMAC (second
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blocks the actions of caspase inhibitors, namely the inhibitor of
apoptosis proteins (IAPs) [16]. Thus, GrB is a powerful pro-
apoptotic factor that activates executioner caspases directly and
through the mitochondrial pathway.
A cell infected with virus becomes a target for destruction by
CTLs via the GrB pathway. However, while under attack, the
production of infectious virus can still occur and be released from
the dying cell. Thus, viral infection of the host would ensue
regardless of cell death. It would make sense if CTLs had a
strategy to stop the virus in its tracks. In addition, to evade host
defenses, viruses have evolved mechanisms to inhibit the caspase-
cascade system. For example, vaccinia virus (VV) expresses the
cytokine response modifier A (CrmA), which is a serine protease
inhibitor or serpin. CrmA is a strong inhibitor of caspase-1, 3, 6
and 8 [1], thereby acting to delay the process of apoptosis. Thus, it
is possible for viruses such as VV to use dying cells for viral
replication. The question arises as to whether CTLs have strategies
to deal with this ongoing production of infectious virus. Recent
literature reveals new roles of human granzymes that extend
beyond apoptosis. Two of these emerging roles involve activation
of the inflammatory system and direct antiviral functions that are
independent of cell death. The ability of granzymes to induce and
process pro-inflammatory cytokines demonstrated that granzymes
activate the inflammatory system [17,18]. Granzymes also have
the potential to directly impair viral replication with an increasing
list of host and viral substrates involved in the replication process
of viruses [18]. GrH can cleave and inactivate host and viral
substrates to prevent viral replication. Romero et al. demonstrated
that GrH-mediated cleavage of the human protein La decreased
hepatitis C virus IRES-mediated translation [19]. One of La’s
roles is to stimulate IRES-mediated translation, a mechanism used
by many viruses to take control of the host translational
machinery. In a different study, Andrade et al. identified
adenovirus protein 100K as a novel GrH substrate [20]. 100K is
important in the assembly of the virus capsid and also functions as
a GrB inhibitor. Thus, the authors uncovered a role in which GrH
inactivated adenovirus replication in a pathway that could
concomitantly de-repress GrB activity. It seems clear that
granzymes have evolved unique antiviral strategies that are
independent of their well-characterized cytolytic roles. In this
study, we propose a novel mechanism for GrB to directly inhibit
the production of VV proteins and thus, inhibit viral replication.
In search for novel GrB substrates, we found eukaryotic
initiation factor 4 gamma 3 (eIF4G3), a protein critical for
initiation of protein translation. In humans, translation is largely
regulated by eukaryotic translation initiation factors (eIF). Detailed
reviews of the events involved in this process have been published
earlier [21,22]. Briefly, a newly transcribed host mRNA is
transported to the cytosol in its linear conformation. Prior to the
initiation of translation, a multi-subunit complex called eIF4F
needs to be formed. Subunits within the complex have important
roles. First, to flank the mRNA, the eIF4E subunit binds to the 59
end of the mRNA, while the poly(A) tail binding protein (PABP)
binds to the 39 end. Following this, the large scaffold subunit
eIF4G3 circularizes the mRNA molecule by binding to both PABP
and eIF4E. The eIF4G3 protein is a central player in the initiation
of translation since it also contains binding domains for mRNA,
eIF4A, and eIF3 (itself a multi-subunit factor that recruits the
ribosome). It is not surprising that many viruses interfere with the
function of the eIF4F complex to gain control of translation. Some
viruses cleave eIF4G3 to halt host protein translation while other
viruses use eIF4G3 to make viral proteins. For example,
rhinoviruses and enteroviruses shut off host protein synthesis by
cleavage of eIF4G3, resulting in inhibition of cap-dependent
translation [23]. Cleavage of eIF4G3 is carried out by the viral-
encoded protease 2A
pro. In contrast, most viruses including
poxviruses, adenoviruses, papillomaviruses, polyomaviruses, her-
pesviruses, and asfarviruses do not cleave eIF4G3, but instead,
take full advantage of the eIF4F complex [24]. VV, a double-
stranded DNA virus of the poxvirus family, cannot replicate in the
absence of eIF4G3 [23,25,26]. VV translates its RNA in a cap-
dependent manner, increases eIF4F complex levels and enhances
PABP binding [24,27]. Thus, we used VV as a model system to
study the role of eIF4G3 degradation by GrB in blocking viral
infection.
We hypothesized that in addition to pro-apoptotic roles, GrB
also targets the translational machinery by cleaving eIF4G3. In the
absence of a functional eIF4G3, translation initiation would be
arrested. In this study, we demonstrate that eIF4G3 cleavage by
GrB is the critical event that prevents VV protein synthesis and
reduces subsequent production of infectious VV particles.
Materials and Methods
Cells and viruses
Jurkat cells were obtained from American Type Culture
Collection (ATCC). Jurkat cells were passaged approximately
every 2 days when cell density reached 1610
6 cells/ml to bring cell
density back to 1610
5 cells/ml. Cells were grown in RPMI
supplemented with 10% fetal bovine serum (FBS), 0.06 mg/ml
penicillin G, and 0.01 mg/ml streptomycin sulfate. Cell number
was then adjusted prior to each experiment as needed for each
method below. Human CTL line was generated as previously
described [28] and maintained in RHFM media containing 90 U
of interleukin 2 (Chiron) per ml. Treatment of Jurkat cells with
CTL generated an allo-response. African ‘‘Buffalo Green’’
Monkey Kidney (BGMK) cells and Vaccinia Virus (VV) were
obtained from ATCC and cultured as previously described [29].
Replication-deficient adenovirus (AD) (type 5) was a generous gift
from Jack Gauldie, McMaster University.
Inhibition of GrB activity
The GrB inhibitor L-038587-00Y001 (GrB inh) was a kind gift
from Dr. Nancy A. Thornberry (Willoughby et al., 2002). The
inhibitor was incubated with GrB for 30 min at a concentration of
10 mMa t3 7 uC prior to treating cells with GrB/AD.
AD-mediated internalization of granzyme B (GrB)
A non-replicating strain of AD was used as previously described
[30] to internalize GrB into cells. AD was used at 1 plaque forming
Author Summary
Lymphocytes, a type of white blood cell, are the major
killer of virus-infected cells. Lymphocytes secrete proteins
like granzyme B that are responsible for the destruction of
the virus-infected host cell. However, killing an infected
cell through this pathway may take several hours, thus
allowing viral replication to occur while the cell is in the
process of dying. In this study, we identified a new role of
granzyme B in preventing viral replication during the
killing process. We found that granzyme B disables the
ability of the host cell to make new proteins, including viral
proteins of infected cells. Thus, granzyme B is able to halt
the production of new viruses by inhibiting protein
production.
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mediated killing of cells.
GrB enzymatic assay
GrB activity was measured in a colorimetric assay [31].
Substrate degradation of Ac-IEPD-pNA (Kaiya Biomedical,
Seattle WA) was monitored at A405. GrB-mediated hydrolysis of
Ac-IEPD-pNA was inhibited in the presence of purified serpina3n
(0.6 to 0.0001 mg/mL) or GrB inh.
Plaque assay
In these experiments, 2.5610
6 Jurkat cells were infected with
VV at a multiplicity of infection (MOI) of 10. Unless otherwise
specified, GrB concentration was 1 mg/ml (,30 nM). AD
concentration was always the same at 10 PFU/cell. All treatments
that contained GrB also contained AD and zVAD-fmk (50 mM,
30 min prior to GrB/AD/VV). Following infection with VV
(6 hr), cells were treated with GrB/AD for 1 hr, washed 3 times in
PBS and then lysed. To estimate the number of VV present in the
cell lysates, plaque assays were performed. BGMK were grown in
monolayers and infected with the cell lysates as previously
described [29].
Cleavage by GrB and mass spectrometry
Jurkat cells were co-treated for 30 min at 37uC with GrB at
1 mg/ml and AD at 10 PFU/cell. Following cell fractionation,
cytosolic fractions were analyzed by 2-Dimensional electrophoresis
and silver staining. This technique was performed as previously
described with some modifications [32]. Cells were centrifuged for
1 min at 18,000 g and the pellet was resuspended in total lysis
buffer and vortexed for 1 min. Proteins were purified and desalted
using the ReadyPrep 2-D Cleanup kit (Bio-Rad, ON, Canada) and
resuspended in 120 ml of rehydration buffer as provided by Bio-
Rad. Samples containing 120 mg of protein were electrofocused on
Immobiline DryStrip pH 3–17, 7 cm IPG strips (GE Healthcare,
NJ, USA) using the IPGphro isoelectric focuser (Pharmacia
Biotech). Strips were equilibrated in ReadyPrep Equilibration
buffers I and II (Bio-Rad) for 30 min in each buffer. Second
dimension was run in Ready Gels 8–16% Tris-HCl, IPG COMB
(Bio-Rad). Following electrophoresis, gels were fixed and silver
stained using the silver staining plus kit (Bio-Rad). Mass
spectrometry analysis was conducted as previously described
[33]. Jurkat cell extracts were also tested by treating with inactive
and active GrB, and ran in 1-Dimensional gels. Gel slices were
analyzed by mass spectrometry at the Manitoba Centre for
Proteomics and Systems Biology.
[
3H]-Thymidine release assay
GrB and CTL-mediated cytolytic activity was measured using
methods that have been previously described [14,34]. 3610
5 cells/
ml of Jurkat cells were labeled with 40 mCi
3H-thyamidine for
20 hr prior to the experiment. Cells were treated with GrB at
1 mg/ml and AD at 10 PFU/cell. Human CTL-mediated killing
was conducted as above with the following modifications. Jurkat
cells were set at 1610
6 cell/ml from 16 ml of total cell suspension.
Cells were treated with a human CTL line [28] at an effector to
target ratio of 5 to 1. Jurkat cells were killed by either GrB
treatment or CD8-mediated killing, then kept in the incubator for
the duration of the experiment. At each time point, triplicates of
200 ml from each tube were collected. A total of 20 time points
were collected, once every 15 min from 0 min to 300 min.
Immediately after collection, 200 ml/tube of lysis buffer (1%
Triton x100 in TE buffer) was added and vortexed for 1 min. Cells
were then centrifuged for 10 min at 18,000 g in a Microfuge 22R
(Beckman Coulter) at 4uC. From the supernatant, 200 ml was
collected and mixed with 5 ml of scintillation fluid. Each
individual tube was counted for 2 min. Total
3H (100%
Detectable DNA) was measured by collecting five-50 ml (quintu-
plicates) samples from each tube above. To each of these five
tubes, 400 ml of total lysis buffer (2% SDS) was added and
vortexed for 1 min. 5 ml of scintillation fluid was added and
samples were counted for 2 min each. Cytolytic activity was
measured by calculating the percentage of specific [
3H]-thymidine
release as follows: 100 x [(sample cmp – spontaneous cmp)/(total
cpm – spontaneous cpm)]. The pan-caspase inhibitor Z-Val-Ala-
Asp(OMe)-CH2F (zVAD-fmk) was used to assess the role of
caspases (Kamiya Biomedical Company, WA, USA). In these
experiments, cells were incubated with 50 mM zVAD-fmk for
30 min prior to GrB treatment.
FITC-annexin V binding
Inversion of phosphatidylserine on apoptotic plasma membrane
was determined by FITC-annexin V binding and flow cytometry
(Kamiya) [35].
Evaluation of protein synthesis
Jurkat cells were pulse-labeled with 33 mCi [
35S]methionine
(PerkinElmer) for 1 hour at a density of 3610
5 cells/ml. Following
treatment, cells were centrifuged for 1 min at 18,000 g. Proteins
were recovered through acetone purification using the ReadyPrep
2-D Cleanup kit. To each protein pellet, we added 400 ml of total
lysis buffer (2% SDS) and vortexed for 1 min. 5 ml of scintillation
fluid was added and samples were counted for 1 min each. Protein
concentration was determined using the BCA assay (Pierce). The
amount of total translated protein was estimated through the
incorporation of Met
S35 per mg of total protein (% Translated
Protein). The highest count per minute (CPM) per mg of protein
for each experiment was considered 100% translated protein. %
Translated Protein was calculated from this value and plotted over
time.
SDS-PAGE
10% acrylamide gels were used. Electrophoresis was run in a
mini protean 3 cell (Bio-Rad) connected to a Power Pac 1000 (Bio-
Rad).
Quantitative PCR (qPCR): This assay was performed as
previously described [36]. b-actin primers were: forward 59-
CGA GAC CAC CTT CAA CTC CAT C-39 and reverse 59-
GCG GTG GAT GGA GGG-39.
In vitro transcription/translation (IVTT) and in vitro
translation (IVT)
The TNT quick-coupled transcription/translation kit was used
(Promega, WI, USA). This kit is a rabbit transcription/translation
system. The translational machinery is thus Rabbit and the
transcriptional machinery is added as a supplement to the rabbit
reticulocyte lysate and is of bacteriophage origin. Master mix
aliquots were thawed by hand warming and placed on ice.
Individual reactions were prepared by combining 40 ml of master
mix with 0.02 mg/ml of template DNA, 0.04 mM [
35S] Methio-
nine (Met
S35) and water up to a total of 50 ml. Tubes were
incubated at 30uC for 90 min. To perform IVT, the above
method was modified by substituting the template DNA with
purified 10 mg/ml mRNA, in the presence of 0.02 U/ml of DNase.
To control for translation, the reaction was arrested by adding
0.01 U/ml of RNase. Radiolabeled proteins were used for in vitro
GrB Inhibits Translation and Virus Production
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Visualization was performed by SDS-PAGE followed by either
silver staining or autoradiography of the dried gels.
In vitro proteolysis
IVTT or IVT reaction products were put on ice immediately
after synthesis. GrB was diluted in PBS to yield a working
concentration of 30 nM unless otherwise specified. Proteolytic
degradation by GrB was carried out in a water bath for 30 min at
37uC and terminated by adding 6 ml of sample solubilizing buffer
(SSB) (0.5 M Tris-HCl, 16% glycerol, 3.2% SDS, 0.8% b-
mercaptoethanol, 10 mg/ml bromophenol blue). The resulting
proteolytic products were visualized by silver staining and
autoradiography (Biomax MR film, Kodak, NY, USA) following
SDS-PAGE.
Mutagenesis
Point mutations were carried out using the Quikchange site-
directed mutagenesis kit (Stratagene, CA, USA). The vector
pcDNA3 containing eIF4G3 was provided by the lab of Dr.
Nahum Sonenberg (McGill University, Canada). Oligonucleotide
primers (Forward 59-GTT GGA CTT CAT AGA GTC TGC
CAG TCC CTG TTC CTC TGA AG-39 and Reverse 59-CTT
CAG AGG AAC AGG GAC TGG CAG ACT CTA TGA AGT
CCA AC-39) were designed to point-mutate aspartate
1408 (D
1408)
to alanine. Mutated plasmids were transformed into competent
DH5a cells (Invitrogen, ON, Canada). Mutations were confirmed
by sequencing the inserts. Successful colonies were purified using
the EndoFree kit (Qiagen, ON, Canada).
Metabolic labeling of VV-infected cells
This technique was carried out as previously described with the
following modifications [37]. Jurkat cells were mock infected or
infected with VV at a MOI of 10 for 0 to 18 hr. 1 hr prior to
termination of infection, Jurkat cells were treated with GrB at
1 mg/ml and AD at 10 PFU/cell. Cells were then starved for
30 min and pulse-labeled with 33 mCi [
35S]methionine and
[
35S]cysteine (PerkinElmer) for 1 hour. Samples were analyzed
by SDS-PAGE followed by autoradiography.
Stable transfection
Human Jurkat cells were transfected with pcDNA3-EIF4G3
and pcDNA3-EIF4G3 asp/ala mutant using the AmaxaH cell line
NucleofectorH (Lonza, Cologne Germany). Briefly, 1.5610
6 cells
were transfected with 2 mg Pvu I linearized plasmids using the
AmaxaH Kit V and the program X-05. The transfected cells were
then transferred to 1 ml pre-warmed RHFM media in a 12 well
plate. After a 24 hr incubation period in a humidified 37uC/5%
CO2 incubator stably transfected cells were selected using 1 mg/
ml G418 (Gibco BRL Life Technologies inc.) and cloned by the
limiting dilution method. Four mutant clones and 12 wild type
clones were selected and maintained in 0.8 mg/ml G418. Two
clones from this group (mutant #4 and wild type #12) were
chosen for further analysis. To confirm the integration of the
plasmid DNA into the host chromosomes, genomic DNA was
extracted from the two clones and a PCR fragment was generated
using the 59 eIF4G3 primer and the 39 bovine growth hormone
primer. The resulting PCR fragment was purified and sequenced.
Affinity chromatography
This technique was conducted using the ProFound Mammalian
HA-Tag IP/Co-IP kit (Pierce, IL, USA). HA-Tagged eIF4G3 and
the mutagenized clone eIF4G3
D were generated through IVTT in
the presence of Met
S35. Following a total of 12 independent IVTT
reactions for each clone, volumes were combined and loaded into
the column. A total of 18 ml of anti-HA agarose slurry (30 mg anti-
HA antibody) was then added to the sample and incubated for
16 hr at 4uC. Columns were then washed 3 times and the HA-
tagged proteins were eluted into a 50 ml final volume. Protein
concentrations were assessed by BCA assay (Pierce). Purification
efficiency and protein identity was assessed respectively by
autoradiography and Western blot analysis.
Western blot analysis
Samples were subjected to 10% SDS-PAGE and proteins were
identified using 1 mg/ml polyclonal anti-eIF4G3 antibody (Ab-
cam, MA, USA).
Densitometric analysis
Blots or films were scanned at 500 dots per inch in the Agfg
Arcus II scanner using Adobe Photoshop. The scanned images
were saved as grey .tif files. Densitometric analysis was performed
with the SigmaGel software. For each reading, a measurement was
taken of the background and subtracted from the reading
generated from the bands. For each film or blot, measurements
were performed 3 times and the average was calculated. A number
in arbitrary units was used to calculate the percent of expression.
Statistical analysis
Results are means 6 S.E. of at least three independent
experiments with the exception of mass spectrometry analysis.
Data were analyzed using one-way analysis of variance (ANOVA),
and when significant differences were found, the multiple
comparison Tukey-Kramer test was used (GraphPad InStat).
Values of P,0.05 were considered statistically significant.
List of accession numbers for mRNAs and proteins
mRNA eIF4G3: NM_001198801
Protein eIF4G3: NP_001185730
mRNA eIF4G1: NM_182917
Protein eIF4G1: NP_886553
mRNA Granzyme B: NM_004131
Protein GrB: NP_004122
mRNA Bid: NM_197966
Protein Bid: NP_932070
mRNA Granzyme A: NM_006144
Protein Granzyme A: NP_006135
mRNA Granzyme K: NM_002104
Protein Granzyme K: NP_002095
mRNA Caspase-3: NM_004346
Protein Caspase-3: NP_004337
Results
GrB cleaves the eukaryotic translation initiation factor 4
gamma 3
To screen for novel GrB substrates, Jurkat cells were treated
with GrB and then monitored for the resulting proteomic change.
Proteomic analysis was conducted through 1D- and 2D-electro-
phoresis analysis (data not shown) and mass spectrometry. eIF4G3
was identified as a candidate using this approach as a spot that
consistently disappear following GrB treatment. Through se-
quence analysis of eIF4G3, we found a sequence very similar to
those cleaved by GrB in the known substrates Bid and caspase-3
(Table S1). Western blot analysis of eIF4G3 expression in Jurkat
cells post GrB/AD treatment showed a significant reduction of
GrB Inhibits Translation and Virus Production
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reduction of detectable eIF4G3 coincided with the appearance of a
cleaved product. The observed degradation of eIF4G3 was not
mediated by caspases since the caspase inhibitor zVAD-fmk did
not prevent degradation of eIF4G3 (Figure 1A). EIF4G3
degradation was significant by 20 min post GrB/Ad treatment
in the absence of caspase activity (Figure 1B left panel). To confirm
that GrB activity was present, we monitored activation of Bid and
Casp-3, two GrB substrates, during our time course analysis of
eIF4G3 degradation. We found that Bid was activated at 60 min,
as demonstrated by the presence of p15 and p13 fragments
(Figure 1A). Active Casp-3 was also detected at 60 min post GrB/
AD treatment (Figure 1A). Conversely, the lack of proteolytic
cleavage of Casp-3 in the presence of zVAD-fmk indicated that
zVAD-fmk inhibited the upstream caspases responsible for
cleavage of Casp-3.
The location of the putative GrB cleavage site (P1 residue) of
eIF4G3 is at aspartate 1408 (D
1408); cleavage at this site would
result in 2 fragments of approximately 180 kDa and 20 kDa in
size. To test whether eIF4G3 is a substrate for GrB, the factor was
synthesized using an in vitro transcription/translation system
(IVTT) in the presence of radioactively labeled methionine
(Met
S35). The radioactively labeled eIF4G3 was then treated with
GrB in vitro and analyzed by electrophoresis and subsequent
autoradiography of the gels (Figure 2). Treatment of labeled
eIF4G3 with 30 nM GrB resulted in the generation of a
proteolytic fragment of eIF4G3, corresponding to the expected
large fragment (Figure 2A). The small fragment expected from the
cleavage of eIF4G3 was not detected in autoradiograms; this
fragment was likely below the detectable limit of autoradiography
as it contains only 3 radioactively labeled Met
S35 residues per
polypeptide, as opposed to 30 Met
S35 residues present in the large
proteolytic fragment. These results suggest that GrB cleaves
eIF4G3 at D
1408.
Factor eIF4G3 is similar to eIF4G1 and may share overlapping
roles in translation. These two proteins share 46% sequence
homology, but eIF4G1 lacks the D
1408 residue. To test if eIF4G1 is
also cleaved by GrB, eIF4G1 was treated with GrB under the same
experimental conditions. Treatment of eIF4G1 with 30 nM GrB
did not result in proteolytic cleavage of this isoform (Figure 2B).
D
1408 is predicted to be the essential residue for cleavage by
GrB. To confirm this, we mutagenized D
1408 to alanine and tested
the effect of this mutation on the proteolytic cleavage of eIF4G3 by
GrB. This mutant (eIF4G3
D) was resistant to 30 nM GrB
treatment (Figure 2C). At a higher concentration of GrB
(300 nM), eIF4G3
D was proteolytically cleaved by GrB. However,
this reaction generated different degradation products suggesting
cleavage at alternative aspartate residues (Figure 2C).
GrB inhibits in vitro translation
Our results showing that eIF4G3 is a substrate of GrB suggests
that GrB can interfere with the translation machinery of target cells.
We used the IVTT system to test whether GrB can inhibit protein
synthesis. The IVTT system uses a master mix that contains
transcription components from bacteriophage and translational
components from rabbit reticulocyte lysate. We used a luciferase
(Luc) DNA template for transcription and subsequent translation in
the presence of Met
S35. Luc protein synthesis was monitored by
SDS-PAGE followed by autoradiography. Next, the in vitro synthesis
of Luc was conducted in the presence or absence of GrB. GrB was
added to the IVTT master mix prior to adding Luc DNA. GrB
treatment reduced synthesis of Luc protein in a concentration-
dependent manner (Figure 3A). At a concentration of 30 nM of
GrB, Luc protein synthesis was no longer detectable with this
technique. Adding GrB to the reaction following in vitro synthesis of
Luc did not degrade Luc protein (Figure 3B), indicating that the
Figure 1. The eukaryotic translation initiation factor eIF4G3 is degraded by GrB (1 mg/ml) in Jurkat (Jkt) cells. (A) Representative
Western blot analysis of detectable full-length eIF4G3 and Bid activation in Jurkat cells from time 0 (no GrB treatment) to 30 min post GrB/AD
treatment (left panel) and in the presence of zVAD-fmk (right panel). (B) Densitometric analysis of eIF4G3 (A) where the eIF4G3/a-tubulin ratio was
calculated and the highest densitometric value was 100%. Other values were plotted as a percentage of the maximum densitometric value. Statistical
significance: p,0.01 (**); (n=3 of 3 independent experiments).
doi:10.1371/journal.ppat.1002447.g001
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expression of Luc and not GrB-dependent degradation of Luc.
In the IVTT system, GrB could be targeting proteins involved
in transcription, translation, or both. In order to determine if GrB
affects mammalian translation independent of transcription, we
used purified Luc mRNA and performed in vitro synthesis of Luc
protein from mRNA. This approach converted the IVTT system
into an in vitro translation (IVT) system. To ensure that the in vitro
synthesis of Luc protein was restricted to translation, DNase was
included in all IVT reactions to eliminate any possible DNA
contaminants. Subsequently, when we added RNase, the synthesis
of Luc protein was completely prevented, demonstrating that
detectable Luc is a result of mRNA translation under our IVT
system (Figure S1). In the presence of 30 nM GrB, IVT was
prevented (Figure 3C). These results demonstrated that GrB was
blocking in vitro synthesis of Luc by interfering at the translational
level. To test whether other proteases had the same effects on
translation, we tested GrB, GrA, GrK, Casp-3, Casp-7 and Casp-8
at concentrations of 3 and 30 nM in the same system (Figure 3D).
GrB was the only enzyme able to completely prevent IVT of Luc
under these conditions. Luminescence from these reactions
indicated that 30 nM GrB, Casp-3 and Casp-7 resulted in a
significant decrease of Luc activity, whereas GrA, GrK and Casp-
8 showed no significant alteration of Luc activity (Figure 3E).
GrB prevents in vitro translation by targeting eIF4G3
To determine whether GrB cleavage of eIF4G3 is responsible
for the GrB-mediated translational inhibition of Luc, we tested
whether supplementing the IVT reaction with the GrB-resistant
mutant eIF4G3
D would regain translation of Luc. Mutant
eIF4G3
D and wild-type eIF4G3 were HA-tagged and purified
using affinity chromatography (Fig S2). Purified GrB-sensitive
eIF4G3 and GrB-resistant eIF4G3
D were then added to the IVT
of Luc, in the presence of GrB. Analysis of Luc protein synthesis
and luminescence showed that recovery of translation was
observed with eIF4G3
D (Figure 4A), but not the wild-type protein
(Figure 4B). Adding 1 and 2 mg/ml of eIF4G3
D-HA to the GrB-
treated IVT led to 22% and 23% recovery of Luc luminescence,
respectively, when compared to the luminescence in untreated Luc
IVT (Figure 4C). The ability of GrB-resistant eIF4G3
D to rescue
GrB-damaged translation machinery indicates that cleavage of
eIF4G3 by GrB is a key event in translational inhibition. Other
substrates may be involved but eIF4G3 is important. To exclude
the possibility that eIF4G3
D rescues translation by inhibiting the
activity of GrB, we performed a GrB enzymatic assay in the
presence of 0.1 – 2 mg/ml of eIF4G3
D. Our positive controls for
the assay included GrB inh and serpina 3n, both of which
significantly reduced GrB activity (Figure 4D). However, eIF4G3
D
did not affect GrB activity at all concentrations tested (Figure 4D).
GrB-dependent translational arrest is
caspase-independent
It is well established that GrB-induced DNA fragmentation, a
hallmark of apoptosis, in Jurkat cells begins at around 30–60 min
and reaches a plateau at around 120 min [38]. We confirmed this
observation by measuring %[
3H]-thymidine release in Jurkat cells
Figure 2. GrB-mediated cleave of eIF4G3 occurs at position D
1408. (A) Autoradiography of eIF4G3 treated with 30 nM GrB for 30 min.
Treatment of eIF4G3 (,200 kDa) with 30 nM GrB generates a proteolytic fragment; (n=3 of 3 independent experiments). (B) The eIF4G3 isoform,
eIF4G1, is not degraded by GrB. Loaded protein levels for eIF4G1 and eIF4G3 lanes are identical to their corresponding GrB treatment lanes; (n=3 of 3
independent experiments). To visualize eIF4G3 fragments, eIF4G3 lanes were loaded at a higher concentration. (C) Putative P1 residue D
1408 of
eIF4G3 was mutagenized to alanine to generate the mutant eIF4G3
D. eIF4G3 and eIF4G3
D were synthesized in vitro and labeled with Met
S35. These
two proteins were treated with 30 and 300 nM GrB. Detectable degradation products are indicated with an arrow; (n=3 of 3 independent
experiments).
doi:10.1371/journal.ppat.1002447.g002
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GrB-induced translational inhibition in relation to the timing of
DNA fragmentation was performed. The incorporation of Met
S35
into newly synthesized proteins at 15 min intervals for 300 min
was measured. A significant reduction in Met
S35-labeled proteins
was detected at 45 min post-GrB treatment, whereas significant
DNA fragmentation was detected at 60 min post-GrB treatment.
The lowered translational rate did not recover after 45 min
(Figure 5A). These results show that translational arrest precedes
the onset of apoptosis as measured by DNA fragmentation, which
was consistent in all 4 independent experiments.
GrB activates several caspases including caspase-3, 7, 8, 9 and
10. To determine if the observed reduction in the translational rate
was mediated by the activation of caspases, we used the pan-
caspase inhibitor zVAD-fmk. As expected, treatment of Jurkat cells
with zVAD-fmk prevented GrB-mediated DNA fragmentation for
the entire 300 min (Figure 5B). The addition of zVAD-fmk
delayed the onset of translational inhibition by GrB to 75 min
(Figure 5B) in comparison to 45 min (Figure 5A) in the absence of
zVAD-fmk. However, translational inhibition by GrB was
maintained even in the presence of zVAD-fmk as evidenced by
the plateau in translation after 75 min (Figure 5B). These findings
suggest that GrB-induced arrest in translation can occur
independently of caspase activity, but that there may be
cooperation between caspase-dependent and caspase-independent
pathways. These results agree with our findings that GrB-mediated
degradation of eIF4G3 is delayed in the presence of zVAD-fmk
(Figure 1A).
Human CTLs reduce translational rate in Jurkat cells
To confirm our findings using a more physiological system, we
tested translational changes using cell-mediated killing in an allo-
response [39]. CTL granules contain a complex proteome that
includes an abundance of GrB. Jurkat cells were treated for
180 min with a human CTL line and assessed for Met
S35
incorporation at 15 min intervals. As expected, CTL-induced
apoptosis in Jurkat cells was prevented in the presence of zVAD-
fmk (Figure 5C). This effect was also observed in Annexin V
binding experiments (Figure S4B). Independent of zVAD-fmk
treatment, CTLs induced a significant reduction of translation by
45 min in Jurkat cells (Figure 5C). These results indicated that
CTL-mediated reduction of translation in target cells takes place
Figure 3. GrB inhibits in vitro translation of Luc. IVTT was used to synthesize Luc in the presence of Met
S35. Labeled Luc protein was visualized
by autoradiography. (A) A range of GrB concentrations (0–30 nM) were added to the IVTT master mix to test their effect on transcription/translation;
(n=3 of 3 independent experiments). (B) Detectable Luc was compared in the absence of GrB, and in the presence of 30 nM GrB added before or
after IVTT; (n=3 of 3 independent experiments). (C) Purified Luc mRNA (10 mg/ml) was used to synthesize Met
S35-labeled Luc. 30 nM GrB prevents
translation; (n=3 of 3 independent experiments). (D) Two different concentrations of proteases (3 and 30 nM) GrB, granzyme A (GrA), granzyme K
(GrK), Caspase-3 (Casp-3), Caspase-7 (Casp-7) and Caspase-8 (Casp-8) were tested in IVTT of Luc; (n=3 of 3 independent experiments). (E)
Luminescence generated by Luc in IVT reactions treated with 30 nM proteases, where sham-treated IVT reactions were considered 100%; Statistical
significance: p,0.01 (**) and p,0.005 (***); (n=3 of 3 independent experiments).
doi:10.1371/journal.ppat.1002447.g003
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inhibitor (L-038587-00Y001), inhibition of CTL-mediated trans-
lational was significantly decreased by 30 min post CTL treatment
(Figure 5D). To confirm that GrB does not affect transcription, we
performed qPCR of b-actin in Jurkat cells in the presence and
absence of GrB/AD. Addition of GrB had no significant effect on
mRNA transcription of b-actin in Jurkat cells; the well-known
transcriptional inhibitor actinomycin D significantly reduced
transcription in this system (Figure 5D).
To measure the effect of CTLs on Jurkat eIF4G3 levels, eIF4G3
protein levels were measured by Western blot. When CTLs were
added to Jurkat cells, a time-dependent reduction in eIF4G3 levels
was observed (Figure S3A). After 10 min treatment, the eIF4G3
signal was not significantly different from CTL alone (Figure S3B).
This suggests that CTL treatment results in degradation of eIF4G3
in Jurkat cells. Furthermore, pre-treating Jurkat cells with zVAD-
fmk did not have any significant effect on detected levels of
eIF4G3, indicating that eIF4G3 degradation is caspase-indepen-
dent (Figure S3B).
Arrest of VV protein synthesis by GrB in Jurkat cells
correlates with GrB-dependent degradation of eIF4G3
Thus far, the experiments looked at global translational
inhibition by GrB. However, the major point of our model is
that viral protein synthesis will be blocked early to halt the
generation of infectious virus. To test this hypothesis, we infected
Jurkat cells with VV and tested viral protein synthesis in the
presence of GrB. During an infection, VV will hijack the host
translational machinery for viral production. Thus, a successful
VV infection is confirmed when only VV proteins are detected.
We monitored protein expression by metabolic labeling. By 12 hr
of infection, there was a near absence of host proteins and
detection of late VV proteins - precursor 4a (P4a), processed
structural proteins 4a and 4b and the early protein E (Figure 6A
upper panel). To test whether late VV protein expression is
affected by GrB treatment, we infected Jurkat cells for 12 hr,
treated with GrB for 1 hr, and then performed metabolic labeling
analysis. Mock infected cells and VV infected cells were run to
compare host versus VV protein expression (Figure 6B upper
panel). GrB treatment reduced VV protein expression, which was
not affected by the caspase inhibitor zVAD-fmk (Figure 6B).
Inactivation of GrB with a specific inhibitor (L-038587-00Y001) or
heat inactivation prior to treatment reversed VV protein
expression, while AD treatment alone did not affect VV protein
expression (Figure 6B). To test whether VV protein expression was
a direct result of GrB-dependent degradation of eIF4G3, we
transfected Jurkat cells and generated stable clones of wild-type
eIF4G3 (Jurkat
eIF4G3-WT) and mutagenized GrB-resistant
eIF4G3
D (Jurkat
eIF4G3D). GrB/AD treatment following 12 hr of
VV infection prevented the formation of detectable VV proteins in
Jurkat cells and in the Jurkat
eIF4G3-WT clone. However, expression
of the GrB-resistant eIF4G3
D reversed the GrB-mediated
protection, resulting in formation of late VV proteins (Figure 6C).
Figure 4. GrB resistant eIF4G3
D can restore in vitro translation of Luc. (A) Translation of Luc mRNA was monitored by autoradiography. In the
presence of 30 nM GrB, translation of Luc is blocked. Purified eIF4G3
D -HA (0.01–2 mg/ml) was added the reaction after GrB treatment to recover Luc
in vitro synthesis. Luc shows as a band at 61 kDa and radio-labeled eIF4G3
D -HA shows as a band at ,200 kDa; (n=3 of 3 independent experiments).
(B) Same experiments as in (A) but with purified wild-type eIF4G3-HA; (n=3 of 3 independent experiments). (C) Luminescence generated by Luc IVT
in (A) was measured and expressed as %Luc luminescence, where expression of Luc with no treatment was considered 100%. Densitometric analysis
was conducted for eIF4G3
D -HA, and expressed as %eIF4G3
D -HA densitometry, where densitometric values for Luc with no treatment was
considered 100%; (n=3 of 3 independent experiments). (D) GrB activity colorimetric assay. GrB inh and purified serpina 3n were used as positive
controls to inhibit GrB activity. Three different concentrations of eIF4G3
D (0.1, 1 and 2 mg/ml) did not inhibit GrB activity; (n=3 of 3 independent
experiments).
doi:10.1371/journal.ppat.1002447.g004
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model where GrB-mediated degradation of eIF4G3 prevents VV
protein expression.
In the absence of GrB, eIF4G3 protein expression did not
change significantly from 0 to 18 hr post infection (Figure 6A
lower panel), while GrB-dependent downregulation of viral
Figure 5. GrB or CTL treatment decrease translational rate in Jurkat cells independently of caspase-mediated DNA fragmentation.
(A and B) Jurkat cells were treated with GrB (1 mg/ml) for 300 min. At 15 min interval, cells were assessed for DNA fragmentation (%[
3H]-Thymidine
Release) and translational rate (% Translated Protein). (B) The pan-caspase inhibitor zVAD-fmk (zV) was used to evaluate the role of caspases. (For (A)
and (B); n=4 of 4 independent experiments). (C) Jurkat cells were treated with CTL for 180 min. As in (A) and (B), DNA fragmentation and translational
rate was assessed at 15 min intervals. Statistical significance: p,0.05 (* and w)p ,0.01 (** and ww); n=3, where * compares statistical significance of
% translated protein of Jurkat cells+zVAD-fmk (Jkt+zV) vs. Jurkat cells+zV+CTL; and w compares Jkt vs. Jkt+CTL; (n=3 of 3 independent experiments).
(D) Jurkat cells were treated with CTL for 90 min in the presence of the GrB inhibitor L-038587-00Y001 (GrB inh). %Translated protein was assessed at
15 min intervals. Statistical significance: p,0.05 (* and w), where * compares statistical significance of % translated protein of Jurkat cells+CTL vs.
Jurkat cells+CTL+L2038587200Y001; (n=3 of 3 independent experiments). (E) qPCR analysis of b-actin (b-act) relative expression at 1 and 2 hr post
GrB/AD treatment; (n=3 of 3 independent experiments).
doi:10.1371/journal.ppat.1002447.g005
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(Figure 6B–C lower panel). This confirmed that cleavage of
eIF4G3 coincides with VV protein expression.
GrB blocks formation of infectious VV particles by
proteolytic cleavage of eIF4G3
To study the effect of GrB on the formation of VV particles, we
used a plaque assay to measure VV titres from infected Jurkat
cells. In our optimization time course experiments, we found that
significant VV production was detected starting at the 6 hr time
point (data not shown). Thus, Jurkat cells were infected with VV
for 6 hr, then treated for 1 hr with increasing concentrations of
GrB in the presence of AD (10 PFU/cell) and zVAD-fmk.
Following treatment, cells were lysed and the cytosolic fraction
was used to infect BGMK cells in a plaque assay. GrB significantly
reduced the production of VV particles from Jurkat cells at 2 and
4 mg/ml (Figure 6D). The metabolic labeling results shown in
Figure 6A–C only detected VV proteins synthesized after GrB
treatment and subsequent addition of [
35S]methionine and
[
35S]cysteine. Thus, only newly synthesized (from metabolic
labeling and onwards) VV proteins, not total VV proteins, are
detected in Figure 6A–C. The plaque assay used in Figure 6D–E is
more sensitive and relevant to our model than the metabolic
labeling of VV proteins. However, this assay cannot distinguish
between VV proteins present before and after GrB treatment. This
is evident in our time course analysis of VV protein synthesis,
where we detect VV proteins at 6 hr post-infection (Figure 6A). By
the time GrB is added at 6 hr post-infection as shown in
Figure 6D–E, these VV proteins have already been made.
Although GrB treatment quickly halts VV protein synthesis, the
already existing VV proteins are not degraded by the addition of
GrB and are still capable of generating new VV particles. This
fundamental difference between the two assays led us to identify
that 2–4 mg/ml of GrB was needed to induce the expected GrB-
mediated reduction in VV titers (Figure 6D).
Expression of GrB-resistant eIF4G3
D resulted in significant
recovery of GrB-dependent translational halt of host protein
synthesis by 2 hr (Figure S4C). Similar results were obtained in
CTL-dependent translational halt (data not shown). The critical
experiment in this study was to test the production of VV from
Jurkat
eIF4G3D cells. We predicted that GrB would be unable to
degrade eIF4G3
D in these cells, thus allowing VV replication in
the presence of GrB. Expression of GrB-resistant eIF4G3
D
reversed the effects of GrB on VV infection, as the production
of VV particles in Jurkat
eIF4G3D was not affected by GrB treatment
(Figure 6E). These experiments indicate that eIF4G3 is a critical
GrB substrate that is targeted to halt production of infectious VV.
Discussion
When a cell is infected with a virus, it becomes a factory for
production of new infectious virus. Immune destruction of the
infected cell ultimately puts a halt to this, but during the killing
process, large amounts of virus could still be produced. It seems
logical to propose that a successful strategy to eradicate virus
infection should also bring a dramatic halt to virus production.
The function of GrB to proteolytically activate pro-apoptotic
factors like caspase-3 and Bid has been extensively investigated
[40]. In this study, we describe a novel role of GrB to block protein
synthesis in a VV-infected cell independently of GrB’s role in
triggering apoptosis. This strategy transforms the host into a
deficient system for viral replication, thus preventing viral spread.
Importantly, we definitively showed that eIF4G3 is the critical
substrate of GrB affected in protein translation.
Proteomic approaches led us to eIF4G3 as a putative GrB
substrate. Within the C-terminal domain of eIF4G3, there is a
sequence similar to that present in Bid and caspase-3, where GrB
cleaves these two substrates (Table S1). The only differing amino
acid in eIF4G3 is the P2 residue (S
1407); however, this serine is
found at the same P2 location in other reported GrB substrates like
centromeric protein b (CENP-B) (Table S1). eIF4G3 was cleaved
in vitro by GrB and in Jurkat cells treated with either GrB or
human CTLs. When we mutagenized the critical aspartate residue
in eIF4G3 to alanine, the resulting mutant (eIF4G3
D) was GrB-
resistant. This evidence demonstrated that D
1408 is the location at
which GrB cleaves eIF4G3.
In order to test whether GrB inhibited protein synthesis, we
used an IVTT system programed by a luciferase gene. When the
IVTT master mix was pretreated with 30 nM GrB, we were
unable to detect protein synthesis or Luc activity. Since this could
occur as a result of disruption of transcription or translation, the
IVTT system was modified to specifically look at translation. This
was achieved by first performing a regular IVTT of Luc. Then,
Luc-mRNA was purified and used as a starting material in a new
synthesis reaction. An important experimental parameter was to
include DNase in the subsequent IVT reactions, to prevent
transcription from any possible DNA that could be present in the
master mix as provided by the manufacturer. This approach was
used to determine that GrB was targeting and disrupting
translation.
Following treatment with GrB, the disabled protein synthesis
system was restored by supplementing the system with eIF4G3
D,
but not with eIF4G3, demonstrating that cleavage of eIF4G3 by
GrB is a critical event in translation inhibition. Recovery of
translation was only partial, thus it is possible that GrB treatment
directly or indirectly targets additional proteins involved in
translation. The capacity of GrB to inhibit in vitro protein synthesis
of Luc was confirmed in Jurkat cells. Within 45 min post-GrB
treatment, translation was completely stopped with no significant
recovery for up to 12 hr (Figure 5 and Figure S4C).
When we treated VV-infected Jurkat cells with GrB, there was a
significant reduction in the synthesis of viral proteins and new
infectious VV particles. Stable transfection of Jurkat cells with the
GrB-resistant eIF4G3
D generated clones that were significantly
more susceptible to VV infection in the presence of GrB. This
experimental approach demonstrated that GrB blocks cap-
dependent translation by specifically targeting eIF4G3 and
cleaving this protein significantly reduces VV production.
In eukaryotes, translational regulation is a critical method to
control gene expression. With the exception of some genes, the
majority of eukaryotic mRNAs are translated through cap-
dependent translation. This process can be separated into the
stages of initiation, elongation, termination and ribosomal
recycling. Translational initiation is the stage where the majority
of regulation takes place. Global regulation of translation initiation
involves eIF inactivation [21]. This approach is used by cells
during starvation or periods of stress and is employed during
apoptosis to allow expression of key regulators. Although
translation inhibition has been reported during apoptosis, we
have shown for the first time that GrB alone can initiate
translational shutoff and in doing so, prevent VV replication.
In this study, we used Jurkat cells. These are commonly used as
targets in CTL and granzyme assays since they die fairly quickly as
revealed in a 4 hr chromium assay. This is in contrast to other
target cells, particularly primary cells in which the time to induce
cell death by GrB is much longer. We have estimated that one VV
particle infecting a single cell can generate one hundred new viral
particles in 24 hr. Thus, over this time frame, the inhibition of
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viruses produce proteins that can inhibit apoptosis, thereby
prolonging the generation of infectious virus. Although not the
focus of this work, the inhibition of protein synthesis may also have
implications for the control of apoptosis during viral infection.
The roles of all three eIF4G isoforms are unclear. It is accepted
that isoform eIF4G2 functions to inhibit translation, while isoforms
eIF4G1 and eIF4G3 are involved in initiation of translation.
Although eIF4G1 and eIF4G3 contain similar domains, they only
share 46% of their sequence. Interestingly, when cap-dependent
translation is inhibited by viruses, degradation of eIF4G3 is the
rate limiting step and not eIF4G1 [23], highlighting the
importance of eIF4G3 in the regulation of translation. Using a
positional proteomic approach, it was reported recently that GrB
can cleave eIF4G1 at an unusual recognition sequence -
CGPD
665F [41]. While it is possible that GrB can cleave both
eIF4G1 and eIF4G3, we found that GrB was unable to cleave
eIF4G1 in our IVTT proteolytic assays.
Cleavage of eIF4G3 at D
1408 r e s u l t si nap r o t e i nw i t hat r u n c a t e d
C-terminaldomain.Wepostulatethatanundescribedfunctionofthis
domain exists. The isoform eIF4G2 acts as general repressor of
translation by inhibiting the functions of eIF4G1 and eIF4G3. Over-
expression of eIF4G2 can inhibit both cap-dependent and IRES-
mediated protein synthesis [42,43]. It is possible that the truncated
Figure 6. Inhibition of VV production by GrB is mediated by cleavage of eIF4G3. (A) Jurkat cells were infected with VV for 0 to 18 hr.
Metabolic labeling was assessed by Met
S35 incorporation and viral protein synthesis was monitored by autoradiography analysis. Arrowheads on the
left hand side of the radiogram indicate host proteins and arrowheads on the right hand side of the radiogram indicate VV proteins. Late VV proteins
P4a, 4a, 4b and early VV protein E are shown. Western blot analysis of eIF4G3 from each time point is shown below the radiogram. (B) Jurkat cells
were infected for 12 hr with no virus (mock) or with VV. Infected cells were co-treated with AD, GrB/AD, GrB/AD+zVAD2fmk (zV), GrB/AD+GrB
inhibitor (inh) and heat inactivated GrB+untreated AD (DGrB/AD). Western blot analysis of eIF4G3 from each experimental condition is shown below
the radiogram. Arrowheads in the Western blot image point to eIF4G3 degradation product; (n=4 of 4 independent experiments). (C) Jurkat cells,
Jurkat cells transformed with wild-type eIF4G3 (Jurkat
eIF4G3-WT) and Jurkat cells transformed with GrB-resistant mutant (Jurkat
eIF4G3-D) were infected
with VV for 12 hr (D) The effect of GrB concentration (1–4 mg/ml) on VV replication was tested. AD and zV concentrations were the same in all
treatments; Statistical significance: p,0.05 (*) and p,0.01 (**); where * compares 2 and 4 mg/ml GrB vs. 0 mg/ml GrB; (n=3 of 3 independent
experiments). (E) VV replication in untreated Jurkat cells, Jurkat
eIF4G3-WT, and Jurkat
eIF4G3D, was measured by plaque assay. Statistical significance:
p,0.01 (**); (n=3 of 3 independent experiments).
doi:10.1371/journal.ppat.1002447.g006
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thus having a dominant negative effect on translation. In concor-
dance with previous studies, we propose that the large proteolytic
fragment of eIF4G3 might have translational inhibitory properties
distinct from degradation of eIF4G3. Alternatively, cleavage may
result in a conformational change of eIF4G3 folding that is
responsible for the loss of its function. Our finding that GrB
inactivates eIF4G3 through proteolytic cleavage with resulting
decrease in protein translation agrees with the current model of
eIF4G3 function. During infection by VV, GrB could also inhibit
translation of specific viral proteins that limit host responses. For
example, by blocking synthesis of CrmA, a serpin from VV that
inhibits caspase activation, GrB would allow caspases to perform their
apoptotic functions.
Synthesis of eIF4G3 and eIF4G1 can occur through the use of
internal IRES elements, independent of cap-mediated translation
[44,45]. In concordance with these results, we found that eIF4G3
downregulation was not detected during infection with VV,
although total host protein synthesis was significantly reduced
(Figure 6A). These results also agree with existing evidence that
VV preserves the eIF4F complex [24] and that VV is unable to
replicate in the absence of eIF4G3 (a subunit of the eIF4F
complex) [23,25].
A number of studies have reported caspase-3-dependent
degradation of eIF4G1 in cells undergoing apoptosis [46,47,48].
In the current study, GrB did not degrade eIF4G1 in vitro;
however, GrB could degrade both eIF4G3 and eIF4G1 in cells
through direct degradation of eIF4G3 and indirectly through
activation of caspase-3. While it has been shown that caspase-3
cleaves eIF4G3 [49], we found that inhibition of caspases by
zVAD-fmk did not prevent GrB-dependent degradation of
eIF4G3 or arrest of translation. However, zVAD-fmk changed
the kinetics of eIF4G3 degradation (Figure 1A–B) and host
translational arrest induced by GrB from 45 min with GrB alone
to 75 min in the presence of zVAD-fmk. This suggests that there is
cooperation between caspase-dependent and caspase-independent
pathways mediated by GrB in the arrest of protein synthesis. We
propose a model where GrB inhibits translation by 1) proteolytic
cleavage of eIF4G3 and 2) indirect degradation of eIF4G1 through
activation of caspase-3.
Since the discovery of GrB, a significant amount of work has
been carried out to decipher the role of GrB in CTL-mediated
killing. We now recognize that GrB, directly and through the
mitochondrial pathway, activates key substrates like caspase-3 and
Bid to induce apoptosis [40]. In this study, we present findings that
suggest a dramatic change of paradigm with regards to the roles of
GrB. The ability of GrB to halt the host translational machinery is
a novel strategy to prevent viral replication in a host cell targeted
by CTLs. This mechanism of GrB has not been described for
other granzymes within the granzyme family of proteases;
specifically, GrA and GrK were unable to inhibit translation.
Although GrH has been shown in literature to inhibit viral
translation by targeting the RNA-binding protein La, they did not
demonstrate an effect of GrH on host translational machinery
[19]. Whether the effect of GrB on translation is due to proteolytic
inactivation of eIF4G3 or that cleavage of eIF4G3 results in
products with new suppressive functions on translation remains to
be determined. Our findings unveil a new antiviral axis of GrB
function to fight viral infection by targeting translation.
Supporting Information
Figure S1 In vitro translation of Luc is performed from purified
Luc mRNA. 1 mg/ml of Luc DNA (vector) was used to synthesize
Luc protein in vitro, showing transcription and translation of Luc.
In the presence of DNase, Luc protein synthesis was blocked.
Purified Luc mRNA is used to synthesize Luc protein from
mRNA, thus restricting the process to translation. In the presence
of DNase, to prevent any Luc DNA contamination. Higher
concentrations of mRNA resulted in higher amount of translated
Luc protein. This reaction was abrogated in the presence of
RNase. This approach converted the IVTT system into an in vitro
translation (IVT) system.
(TIF)
Figure S2 Purification of HA-tagged eIF4G3. (A) Diagram
representing reported domains within the eIF4G3 sequence and
the location of the HA-tag. GrB cleavage site is indicated with an
arrow (D
1408). (B) To monitor the effectiveness of the chromato-
graphic approach, we ran SDS-PAGE followed by silver staining
of the samples at different stages of the purification. Naı ¨ve MM
indicates a master mix that was not altered in any way. MM
eIF4G3
D-HA indicates master mix after IVTT of eIF4G3
D-HA.
1
st,2
nd and 3
rd flow through refer to 3 consecutive washes of the
columns. Purified eIF4G3
D-HA refers to eluted fraction (C) The
same gel was then dried and analyzed by autoradiography. (D)
The silver stained gel and the autoradiography film were
superimposed and shown at higher resolution. The same approach
was used for HA-tagged wild-type eIF4G3. (E) Purified products
were detected by Western blot analysis at a concentration of
0.1 mg of purified protein per lane.
(TIF)
Figure S3 CTL-treatment of Jurkat cells induces eIF4G3
degradation. (A) Expression of eIF4G3 was accessed by Western
blot analysis in the first 30 min after treating Jurkat cells with CTL
in the absence of zVAD-fmk (no zV) or in its presence (+zV). (B)
Densitometric analysis of (A) where the eIF4G3/b-actin (b-act)
ratio was calculated and the highest densitometric value was a
100%. The data was plotted as a percentage of the maximum
densitometric value. Statistical significance: p,0.01 (**); (n=6 of 6
independent experiments).
(TIF)
Figure S4 GrB and CTL-induced changes in apoptosis and
translation. Jurkat cells were treated with (A) GrB/AD and (B) CTL
for 24 hr. %Annexin positive cells were measured at 1 hr intervals
up to 6 hr and then at 12 hr and 24 hr. Sham treatment included
AD at a concentration of 10 PFU/cell. For (A and B) statistical
significance of p,0.01 (**) is shown where * compares statistical
significance of Jurkat cells treated with CTL vs. Jurkat cells treated
with CTL in the presence of zV; (n=5 of 5 independent
experiments). (C–E) Untreated Jurkat cells, Jurkat cells transfected
with wild-type eIF4G3 (Jurkat
eIF4G3-WT) and Jurkat cells transfected
with the GrB-resistant eIF4G3 mutant (Jurkat
eIF4G3D) were treated
with GrB and AD (GrB/AD). (C and D) DNA fragmentation was
measuredas%[3H]-Thymidinerelease(C)intheabsenceofzVAD-
fmk (no zV) and (D and E) in the presence of zVAD-fmk (+zV). (E)
%Translated protein was measured; Statistical significance: p,0.05
(* and w)p ,0.01 (** and ww); where * compares statistical
significance of Jurkat
eIF4G3-WT+GrB/AD vs. Jurkat
eIF4G3D+GrB/
AD; and w compares statistical significance of Jurkat+GrB/AD vs.
Jurkat
eIF4G3D+GrB/AD; (For C–E, n=3 of 3 independent
experiments).
(TIF)
Table S1 Sequence alignment for GrB substrate cleavage sites,
related to Figure 2. GrB cleaves these substrates between the
Aspartate at the P1 and the P1’ residue. The 5 residues shown for
each substrate (P4 to P1’) are critical for GrB catalytic cleavage.
GrB Inhibits Translation and Virus Production
PLoS Pathogens | www.plospathogens.org 12 December 2011 | Volume 7 | Issue 12 | e1002447The GrB substrates are Caspase-3 (casp-3), BH3 Interacting
domain Death agonist (Bid), eukaryotic initiation factor 4 gamma
3 (eIF4G3), and centromeric protein b (CENP-B).
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